Novel treatments to counteract primary resistance to anti-EGFR therapy will continue to be explored. The emergent mechanisms of resistance to anti-EGFR targeting in KRASwild-type tumors will be ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...

The IPASS (Iressa Pan-Asia Study) is the first large randomized clinical trial that compared first-line EGFR TKI therapy with chemotherapy. 1 In this study, 1,217 Asian non-smokers or former light ...

Johnson & Johnson CEO highlights Lecrazas potential to transform lung cancer treatment Johnson & Johnsons leader underscores ...

South Korea’s first domestically developed anti-cancer drug approved by the U.S. Food and Drug Administration (FDA), has ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

“This Breakthrough Therapy Designation reinforces datopotamab deruxtecan as a promising potential therapy for patients with EGFR-mutated lung ... of a humanized anti-TROP2 IgG1 monoclonal ...

WILMINGTON, Del.--(BUSINESS WIRE)--Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or ...

US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins: Shanghai Thursday, January 9, 2025, 1 ...